Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 0.55
SHPGF's Cash to Debt is ranked higher than
52% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. SHPGF: 0.55 )
SHPGF' s 10-Year Cash to Debt Range
Min: 0.09   Max: No Debt
Current: 0.55

Equity to Asset 0.57
SHPGF's Equity to Asset is ranked higher than
67% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SHPGF: 0.57 )
SHPGF' s 10-Year Equity to Asset Range
Min: 0.25   Max: 0.85
Current: 0.57

0.25
0.85
Interest Coverage 45.50
SHPGF's Interest Coverage is ranked higher than
54% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SHPGF: 45.50 )
SHPGF' s 10-Year Interest Coverage Range
Min: 2.96   Max: 45.5
Current: 45.5

2.96
45.5
F-Score: 5
Z-Score: 6.58
M-Score: -2.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 31.59
SHPGF's Operating margin (%) is ranked higher than
96% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. SHPGF: 31.59 )
SHPGF' s 10-Year Operating margin (%) Range
Min: -56.61   Max: 35.13
Current: 31.59

-56.61
35.13
Net-margin (%) 22.43
SHPGF's Net-margin (%) is ranked higher than
94% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. SHPGF: 22.43 )
SHPGF' s 10-Year Net-margin (%) Range
Min: -59.59   Max: 24.16
Current: 22.43

-59.59
24.16
ROE (%) 23.16
SHPGF's ROE (%) is ranked higher than
96% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. SHPGF: 23.16 )
SHPGF' s 10-Year ROE (%) Range
Min: -91.39   Max: 30.9
Current: 23.16

-91.39
30.9
ROA (%) 12.77
SHPGF's ROA (%) is ranked higher than
95% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. SHPGF: 12.77 )
SHPGF' s 10-Year ROA (%) Range
Min: -37.86   Max: 14.8
Current: 12.77

-37.86
14.8
ROC (Joel Greenblatt) (%) 140.34
SHPGF's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. SHPGF: 140.34 )
SHPGF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -416.27   Max: 315.7
Current: 140.34

-416.27
315.7
Revenue Growth (%) 10.80
SHPGF's Revenue Growth (%) is ranked higher than
85% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: -1.90 vs. SHPGF: 10.80 )
SHPGF' s 10-Year Revenue Growth (%) Range
Min: -1   Max: 54.2
Current: 10.8

-1
54.2
EBITDA Growth (%) 22.80
SHPGF's EBITDA Growth (%) is ranked higher than
91% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. SHPGF: 22.80 )
SHPGF' s 10-Year EBITDA Growth (%) Range
Min: -0.7   Max: 66.3
Current: 22.8

-0.7
66.3
EPS Growth (%) 32.00
SHPGF's EPS Growth (%) is ranked higher than
93% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. SHPGF: 32.00 )
SHPGF' s 10-Year EPS Growth (%) Range
Min: -5.6   Max: 61.5
Current: 32

-5.6
61.5
» SHPGF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with SHPGF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 33.80
SHPGF's P/E(ttm) is ranked higher than
94% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SHPGF: 33.80 )
SHPGF' s 10-Year P/E(ttm) Range
Min: 14.74   Max: 74
Current: 33.8

14.74
74
P/B 6.60
SHPGF's P/B is ranked higher than
71% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. SHPGF: 6.60 )
SHPGF' s 10-Year P/B Range
Min: 2.03   Max: 14.39
Current: 6.6

2.03
14.39
P/S 7.30
SHPGF's P/S is ranked higher than
85% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. SHPGF: 7.30 )
SHPGF' s 10-Year P/S Range
Min: 2.23   Max: 9.26
Current: 7.3

2.23
9.26
PFCF 22.60
SHPGF's PFCF is ranked higher than
97% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SHPGF: 22.60 )
SHPGF' s 10-Year PFCF Range
Min: 9.79   Max: 42.14
Current: 22.6

9.79
42.14
EV-to-EBIT 24.67
SHPGF's EV-to-EBIT is ranked higher than
94% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SHPGF: 24.67 )
SHPGF' s 10-Year EV-to-EBIT Range
Min: -21.2   Max: 34.4
Current: 24.67

-21.2
34.4
PEG 1.91
SHPGF's PEG is ranked higher than
98% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SHPGF: 1.91 )
SHPGF' s 10-Year PEG Range
Min: 0.99   Max: 2.81
Current: 1.91

0.99
2.81
Shiller P/E 49.40
SHPGF's Shiller P/E is ranked higher than
96% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SHPGF: 49.40 )
SHPGF' s 10-Year Shiller P/E Range
Min: 30.76   Max: 143.7
Current: 49.4

30.76
143.7
Current Ratio 1.43
SHPGF's Current Ratio is ranked higher than
54% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. SHPGF: 1.43 )
SHPGF' s 10-Year Current Ratio Range
Min: 0.67   Max: 7.43
Current: 1.43

0.67
7.43
Quick Ratio 1.16
SHPGF's Quick Ratio is ranked higher than
54% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. SHPGF: 1.16 )
SHPGF' s 10-Year Quick Ratio Range
Min: 0.53   Max: 7.07
Current: 1.16

0.53
7.07

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.30
SHPGF's Dividend Yield is ranked lower than
86% of the 194 Companies
in the Global Biotechnology industry.

( Industry Median: 1.13 vs. SHPGF: 0.30 )
SHPGF' s 10-Year Dividend Yield Range
Min: 0.19   Max: 0.68
Current: 0.3

0.19
0.68
Dividend Payout 0.07
SHPGF's Dividend Payout is ranked higher than
100% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SHPGF: 0.07 )
SHPGF' s 10-Year Dividend Payout Range
Min: 0.05   Max: 1.23
Current: 0.07

0.05
1.23
Dividend growth (3y) 15.70
SHPGF's Dividend growth (3y) is ranked higher than
91% of the 90 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. SHPGF: 15.70 )
SHPGF' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 57.7
Current: 15.7

0
57.7
Yield on cost (5-Year) 0.56
SHPGF's Yield on cost (5-Year) is ranked lower than
71% of the 199 Companies
in the Global Biotechnology industry.

( Industry Median: 1.17 vs. SHPGF: 0.56 )
SHPGF' s 10-Year Yield on cost (5-Year) Range
Min: 0.36   Max: 1.28
Current: 0.56

0.36
1.28

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 2.12
SHPGF's Price/DCF (Projected) is ranked higher than
96% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SHPGF: 2.12 )
SHPGF' s 10-Year Price/DCF (Projected) Range
Min: 1.01   Max: 2.65
Current: 2.12

1.01
2.65
Price/Median PS Value 1.80
SHPGF's Price/Median PS Value is ranked higher than
77% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. SHPGF: 1.80 )
SHPGF' s 10-Year Price/Median PS Value Range
Min: 0.57   Max: 2.48
Current: 1.8

0.57
2.48
Price/Peter Lynch Fair Value 1.97
SHPGF's Price/Peter Lynch Fair Value is ranked higher than
98% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SHPGF: 1.97 )
SHPGF' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.72   Max: 2.92
Current: 1.97

0.72
2.92
Earnings Yield (Greenblatt) 4.10
SHPGF's Earnings Yield (Greenblatt) is ranked higher than
93% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. SHPGF: 4.10 )
SHPGF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.9   Max: 14.5
Current: 4.1

2.9
14.5
Forward Rate of Return (Yacktman) 17.99
SHPGF's Forward Rate of Return (Yacktman) is ranked higher than
94% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -6.41 vs. SHPGF: 17.99 )
SHPGF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.3   Max: 24.1
Current: 17.99

1.3
24.1

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:SHPG.USA, SHP.UK, S7E.Germany, SP2.Germany
Shire PLC was registered in Jersey on 28th January, 2008. It is a specialty biopharmaceutical company that focuses on developing and marketing specialty medicines that address significant unmet patient needs. The Company unified its business during 2013 by integrating the operations of the Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT) and Regenerative Medicine (RM) business units into a simplified One Shire organization. The Company has four commercial units that focus exclusively on the commercial execution of its In-Line products in the following specialist therapeutic areas: Rare Diseases, Neuroscience, Gastrointestinal (GI) and Internal Medicine. The clinical development, manufacturing and marketing of the Company's products is subject to governmental regulation in the US, the EU and other territories.
» More Articles for SHPGF

Headlines

Articles On GuruFocus.com
David Tepper Buys 4 New Stocks in Q3 Nov 18 2014 
Invesco European Growth Fund Q3 2014 Commentary Oct 29 2014 
Weekly 52-Week Highs Highlight: KSS, SHPG, LB, RSG Sep 28 2014 
Invesco European Growth Fund Comments on Shire PLC Jul 29 2014 
Invesco European Growth Fund Second Quarter 2014 Commentary Jul 29 2014 
Weekly 52-Week Highs Highlight: SHPG, ILMN, UA, WDAY Feb 23 2014 
Paulson Says Bet Against Europe to Blame for Down Year, Slashed EU Holdings in Q3 Dec 06 2012 
John Paulson’s 4 Stocks Trading at 52-Week Lows Nov 28 2012 
Top 4 International Stocks at 52-Week Low Prices Oct 31 2012 

More From Other Websites
Broadband changes may threaten Comcast's bid for Time Warner Nov 11 2014
Shire to Present at the Jefferies 2014 Global Healthcare Conference Jun 02 2014
Shire to Present at the Jefferies 2014 Global Healthcare Conference Jun 02 2014
Shire submits INTUNIV® (guanfacine extended release) Marketing Authorisation Application to EMA Mar 28 2014
2013 Annual Report - DTR 6.3.5 Disclosure Mar 27 2014
2013 Annual Report – DTR 6.3.5 Disclosure Mar 27 2014
Shire Pharmaceuticals Initiates Voluntary Nationwide Recall Of One Batch, Packaged into Three Lots,... Mar 14 2014
Director Declaration Mar 14 2014
Director/PDMR Shareholding Mar 07 2014
Director/PDMR Shareholding Mar 06 2014
Shire to present at the Cowen and Company 34th Annual Health Care Conference Mar 04 2014
Elections for Interim Dividend Mar 03 2014
Elections for Interim Dividend in Respect of the Six Months to December 31, 2013 Mar 03 2014
Director/PDMR Shareholding Mar 03 2014
Total Voting Rights Mar 03 2014
Shire Recognizes Rare Disease Day 2014 Feb 28 2014
STATEMENT RELATING TO SHIRE’S VPRIV® (VELAGLUCERASE ALFA FOR INJECTION) PRESS RELEASE DATED JUNE... Feb 25 2014
ViroPharma announces results of tender offer for its 2.00% Convertible Senior Notes Due 2017 (49KB... Feb 25 2014
Director’s Share Dealings Feb 21 2014
Director’s Share Dealings Feb 21 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK